决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
这些结果表明,铰链长度调节提供了一种可编程策略,用于调节靶向膜近端表位的 CARs 的抗原敏感性,并可用于 CAR 优化和提高肿瘤选择性。
表皮生长因子受体(EGFR)常在多种实体瘤中过表达,是嵌合抗原受体(CAR)T细胞疗法的理想靶点;但健康组织也有低水平EGFR表达,因此治疗策略必须平衡抗原应答能力与靶向肿瘤外正常组织所致毒性风险。本研究发现多种骆驼科单域抗体(纳米抗体)可作为有效的EGFR靶向CAR识别结构域(EGFR-sdCAR),对EGFR高表达和低表达靶细胞均有很强反应。为降低其强抗原敏感性,研究者逐步截短了多种CAR构建体常用作间隔区的人CD8铰链区。铰链区每次截短一个氨基酸,均逐步降低EGFR-sdCAR-Jurkat细胞与EGFR阳性靶细胞的结合,并降低CD69激活标志物表达。铰链区截短后信号减弱,使EGFR-sdCAR更具选择性,偏向EGFR高表达的抗原密集型肿瘤细胞,而非EGFR低表达肿瘤细胞或健康供者来源的EGFR阳性成纤维细胞。研究还提供证据表明,表位位置决定CAR对铰链区的需求:截短铰链区同样会降低靶向HER2膜近端表位CAR的抗原敏感性,但不会降低靶向EGFRvIII膜远端表位CAR的敏感性。体外和体内实验均显示,铰链修饰后的EGFR-sdCAR细胞在Jurkat-CAR-T细胞及多名供者的原代人CAR-T细胞中具有明确的功能减弱。总体而言,调节铰链长度为控制靶向膜近端表位CAR的抗原敏感性提供了一种可编程策略,可用于优化CAR并提高肿瘤选择性。
Epidermal growth factor family receptor (EGFR) is commonly overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR)-T therapy, but as EGFR is also expressed at lower levels in healthy tissues a therapeutic strategy must balance antigenic responsiveness against the risk of on-target off-tumor toxicity. Herein, we identify several camelid single-domain antibodies (also known as nanobodies) that are effective EGFR targeting moieties for CARs (EGFR-sdCARs) with very strong reactivity to EGFR-high and EGFR-low target cells. As a strategy to attenuate their potent antigenic sensitivity, we performed progressive truncation of the human CD8 hinge commonly used as a spacer domain in many CAR constructs. Single amino acid hinge-domain truncation progressively decreased both EGFR-sdCAR-Jurkat cell binding to EGFR-expressing targets and expression of the CD69 activation marker. Attenuated signaling in hinge-truncated EGFR-sdCAR constructs increased selectivity for antigen-dense EGFR-overexpressing cells over an EGFR-low tumor cell line or healthy donor derived EGFR-positive fibroblasts. We also provide evidence that epitope location is critical for determining hinge-domain requirement for CARs, as hinge truncation similarly decreased antigenic sensitivity of a membrane-proximal epitope targeting HER2-CAR but not a membrane-distal EGFRvIII-specific CAR. Hinge-modified EGFR-sdCAR cells showed clear functional attenuation in Jurkat-CAR-T cells and primary human CAR-T cells from multiple donors in vitro and in vivo . Overall, these results indicate that hinge length tuning provides a programmable strategy for throttling antigenic sensitivity in CARs targeting membrane-proximal epitopes, and could be employed for CAR-optimization and improved tumor selectivity.
MEMBER ACCOUNT
登录成功会直接打开下一页。